UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)

Annals of oncology, 2019-05, Vol.30, p.iii21-iii21

2019

Volltextzugriff (PDF)

Grafts of Schwann cells engineered to express PSA-NCAM promote functional recovery after spinal cord injury

Brain (London, England : 1878), 2007-08, Vol.130 (8), p.2159-2174

2007

Volltextzugriff (PDF)

Mining the effect of the neonicotinoids imidacloprid and clothianidin on the chemical homeostasis and energy equilibrium of primary mouse neural stem/progenitor cells using metabolomics

Pesticide biochemistry and physiology, 2020-09, Vol.168, p.104617-104617, Article 104617

2020

Volltextzugriff (PDF)

Schwann cell transplantation for CNS repair

Current medicinal chemistry, 2008, Vol.15 (2), p.151-160

2008

Volltextzugriff (PDF)

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

European urology open science (Online), 2022-08, Vol.42, p.S10

2022

Volltextzugriff (PDF)

1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)

Annals of oncology, 2023-10, Vol.34, p.S781-S782

2023

Volltextzugriff (PDF)

EP12.02-06 Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC)

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S676

2023

Volltextzugriff (PDF)

EP12.02-11 Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S678-S679

2023

Volltextzugriff (PDF)

111P Real-world treatment modification of first-line axitinib + pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)

Annals of oncology, 2021-12, Vol.32, p.S1423-S1424

2021

Volltextzugriff (PDF)

EP12.02-02 Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S674

2023

Volltextzugriff (PDF)

Emx1 is a Marker for Pyramidal Neurons of the Cerebral Cortex

Cerebral cortex (New York, N.Y. 1991), 2001-12, Vol.11 (12), p.1191-1198

2001

Volltextzugriff (PDF)

P2.10-14 First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S358

2023

Volltextzugriff (PDF)

75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy

Annals of oncology, 2021-12, Vol.32, p.S1404-S1405

2021

Volltextzugriff (PDF)

PCR234 Patient and Oncologist Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer (ALK+ aNSCLC) Tyrosine Kinase Inhibitors (TKIs) Treatments in the First Line (1L) Setting

Value in health, 2024-06, Vol.27 (6), p.S339-S339

2024

Volltextzugriff (PDF)

979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study

Annals of oncology, 2022-09, Vol.33, p.S998-S999

2022

Volltextzugriff (PDF)

PP01.38 Biomarker Testing and Associated Treatment patterns in Advanced Non-Small Cell Lung Cancer in the US

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e26-e26

2023

Volltextzugriff (PDF)

PP01.37 Quality of Life in Non-Small Cell Lung Cancer Patients With Brain/CNS Metastases– Real-world evidence

Journal of thoracic oncology, 2023-03, Vol.18 (3), p.e26-e26

2023

Volltextzugriff (PDF)

66PDual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)

Annals of oncology, 2019-05, Vol.30 (Supplement_3)

2019

Volltextzugriff (PDF)

EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil

Value in health, 2022-12, Vol.25 (12), p.S82-S82

2022

Volltextzugriff (PDF)

Gap junctions in the adult cerebral cortex: Regional differences in their distribution and cellular expression of connexins

Journal of comparative neurology (1911), 1996-12, Vol.376 (2), p.326-342

1996

Volltextzugriff (PDF)

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

Annals of oncology, 2021-09, Vol.32, p.S690-S691

2021

Volltextzugriff (PDF)

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S456-S457

2022

Volltextzugriff (PDF)

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Annals of oncology, 2019-10, Vol.30, p.v359-v360

2019

Volltextzugriff (PDF)

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Annals of oncology, 2019-10, Vol.30, p.v359-v360

2019

Volltextzugriff (PDF)

908PDPrimary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1 – 25 von 55

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(55)

Sprache

Englisch
(54)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Dual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)

Grafts of Schwann cells engineered to express PSA-NCAM promote functional recovery after spinal cord injury

Mining the effect of the neonicotinoids imidacloprid and clothianidin on the chemical homeostasis and energy equilibrium of primary mouse neural stem/progenitor cells using metabolomics

Schwann cell transplantation for CNS repair

Role of prior nephrectomy for synchronous metastatic Renal Cell Carcinoma (mRCC) on efficacy in patients treated with Avelumab + Axitinib (A + Ax) or Sunitinib (S): Results from JAVELIN Renal 101

1360P Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK+ patients with (w) and without (w/o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)

EP12.02-06 Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC)

EP12.02-11 Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib

111P Real-world treatment modification of first-line axitinib + pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)

EP12.02-02 Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs

Emx1 is a Marker for Pyramidal Neurons of the Cerebral Cortex

P2.10-14 First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs

75P Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib + checkpoint inhibitor (CPI) therapy

PCR234 Patient and Oncologist Preferences for Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer (ALK+ aNSCLC) Tyrosine Kinase Inhibitors (TKIs) Treatments in the First Line (1L) Setting

979P Long-term intracranial safety and efficacy analyses from the phase III CROWN study

PP01.38 Biomarker Testing and Associated Treatment patterns in Advanced Non-Small Cell Lung Cancer in the US

PP01.37 Quality of Life in Non-Small Cell Lung Cancer Patients With Brain/CNS Metastases– Real-world evidence

66PDual targeting of RANKL/RANK pathway and HER-2 as a novel treatment strategy in HER-2 positive (+) breast carcinomas (BC)

EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil

Gap junctions in the adult cerebral cortex: Regional differences in their distribution and cellular expression of connexins

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

EP08.02-115 A Retrospective, Multicenter, Observational Study to Evaluate Outcomes With Lorlatinib After Alectinib in ALK+ NSCLC in Japan

908PD - Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Primary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

908PDPrimary renal tumour shrinkage in patients (pts) who did not undergo upfront cytoreductive nephrectomy (uCN): Subgroup analysis from the phase III JAVELIN Renal 101 trial of first-line avelumab + axitinib (A + Ax) vs sunitinib (S) for advanced renal cell carcinoma (aRCC)

Suchergebnisse filtern